NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, Sébastien Carrère, Anne Ducassou, Marie-Pierre Sunyach, Peter Agoston, Angela Hong, Augustin Mervoyer, Marco Rastrelli, Victor Moreno, Rubi K Li, Béatrice Tiangco, Antonio Casado Herraez, Alessandro Gronchi, László Mangel, Teresa Sy-Ortin, Peter Hohenberger, Thierry de Baère, Axel Le Cesne, Sylvie Helfre, Esma Saada-Bouzid, Aneta Borkowska, Rodica Anghel, Ann Co, Michael Gebhart, Guy Kantor, Angel Montero, Herbert H Loong, Ramona Vergés, Lore Lapeire, Sorin Dema, Gabriel Kacso, Lyn Austen, Laurence Moureau-Zabotto, Vincent Servois, Eva Wardelmann, Philippe Terrier, Alexander J Lazar, Judith V M G Bovée, Cécile Le Péchoux, Zsusanna Papai

Open source

DOI: 10.1016/s1470-2045(19)30326-2
Published: 2019-08
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-19-30326-2,
  title = {NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial},
  author = {Sylvie Bonvalot and Piotr L Rutkowski and Juliette Thariat and Sébastien Carrère and Anne Ducassou and Marie-Pierre Sunyach and Peter Agoston and Angela Hong and Augustin Mervoyer and Marco Rastrelli and Victor Moreno and Rubi K Li and Béatrice Tiangco and Antonio Casado Herraez and Alessandro Gronchi and László Mangel and Teresa Sy-Ortin and Peter Hohenberger and Thierry de Baère and Axel Le Cesne and Sylvie Helfre and Esma Saada-Bouzid and Aneta Borkowska and Rodica Anghel and Ann Co and Michael Gebhart and Guy Kantor and Angel Montero and Herbert H Loong and Ramona Vergés and Lore Lapeire and Sorin Dema and Gabriel Kacso and Lyn Austen and Laurence Moureau-Zabotto and Vincent Servois and Eva Wardelmann and Philippe Terrier and Alexander J Lazar and Judith V M G Bovée and Cécile Le Péchoux and Zsusanna Papai},
  year = {2019},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(19)30326-2},
  url = {https://doi.org/10.1016/s1470-2045(19)30326-2}
}

RIS

TY  - JOUR
TI  - NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
AU  - Sylvie Bonvalot
AU  - Piotr L Rutkowski
AU  - Juliette Thariat
AU  - Sébastien Carrère
AU  - Anne Ducassou
AU  - Marie-Pierre Sunyach
AU  - Peter Agoston
AU  - Angela Hong
AU  - Augustin Mervoyer
AU  - Marco Rastrelli
AU  - Victor Moreno
AU  - Rubi K Li
AU  - Béatrice Tiangco
AU  - Antonio Casado Herraez
AU  - Alessandro Gronchi
AU  - László Mangel
AU  - Teresa Sy-Ortin
AU  - Peter Hohenberger
AU  - Thierry de Baère
AU  - Axel Le Cesne
AU  - Sylvie Helfre
AU  - Esma Saada-Bouzid
AU  - Aneta Borkowska
AU  - Rodica Anghel
AU  - Ann Co
AU  - Michael Gebhart
AU  - Guy Kantor
AU  - Angel Montero
AU  - Herbert H Loong
AU  - Ramona Vergés
AU  - Lore Lapeire
AU  - Sorin Dema
AU  - Gabriel Kacso
AU  - Lyn Austen
AU  - Laurence Moureau-Zabotto
AU  - Vincent Servois
AU  - Eva Wardelmann
AU  - Philippe Terrier
AU  - Alexander J Lazar
AU  - Judith V M G Bovée
AU  - Cécile Le Péchoux
AU  - Zsusanna Papai
PY  - 2019
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(19)30326-2
UR  - https://doi.org/10.1016/s1470-2045(19)30326-2
ER  -

APA

Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R. K., Tiangco, B., Herraez, A. C., Gronchi, A., Mangel, L., Sy-Ortin, T., Hohenberger, P., Baère, T. D., Cesne, A. L., Helfre, S., Saada-Bouzid, E., Borkowska, A., Anghel, R., Co, A., Gebhart, M., Kantor, G., Montero, A., Loong, H. H., Vergés, R., Lapeire, L., Dema, S., Kacso, G., Austen, L., Moureau-Zabotto, L., Servois, V., Wardelmann, E., Terrier, P., Lazar, A. J., Bovée, J. V. M. G., Péchoux, C. L., & Papai, Z. (2019). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30326-2

Source records

crossref · retrieved 2026-09-25T17:58:55.037Z